NCT05199493 (AIDED) is a Phase 3 clinical trial of Angiotensin II in Cardiac Surgery, sponsored by Universität Münster.

Who is sponsoring NCT05199493?

NCT05199493 is sponsored by Universität Münster.

What drugs are being tested in NCT05199493?

Interventions in NCT05199493: Angiotensin II, Control.

What condition does NCT05199493 study?

NCT05199493 studies Cardiac Surgery, Vasoplegia, Hyperreninemia.

Is NCT05199493 still recruiting?

NCT05199493 is currently completed. Last updated 24 March 2023.

Last reviewed 2023-03-24 · How we verify

NCT05199493: AIDED

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reducing Acute Kidney Injury Occurence by Administering Angiotensin II

Completed Phase 3 Last updated 24 March 2023

What this trial tests

Phase 3 trial testing Angiotensin II in Cardiac Surgery in 64 participants. Completed in 19 March 2023.

Timeline

27 December 2021

Primary endpoint
19 December 2022

19 March 2023

Quick facts

Lead sponsor	Universität Münster
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	64
Start date	27 December 2021
Primary completion	19 December 2022
Estimated completion	19 March 2023
Sites	1 location across Germany

Drugs / interventions tested

Angiotensin II (ANGIOTENSIN II) — full drug profile →
Control

Conditions studied

Cardiac Surgery — all drugs for Cardiac Surgery →
Vasoplegia — all drugs for Vasoplegia →
Hyperreninemia — all drugs for Hyperreninemia →

Sponsor

Universität Münster — full company profile →

Who can join

18 and older, any sex, with Cardiac Surgery or Vasoplegia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate whether adding angiotensin II to the standard of care is superior compared to the standard of care alone with respect to kidney damage (personalized approach) after cardiac surgery.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

New drugs for acute kidney injury.
Hariri G, Legrand M. · · 2025 · cited 8× · PMID 39872831 · DOI 10.1016/j.jointm.2024.08.001

Verify or expand the search:

Other trials of Angiotensin II

Trials testing the same drug.

NCT06157580 — Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia · EARLY_PHASE1 · completed
NCT05824767 — Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock · Phase 4 · completed
NCT04901169 — Angiotensin II in Liver Transplantation · Phase 2, PHASE3 · active not recruiting
NCT04904562 — Angiotensin II for Distributive Shock · Phase 4 · terminated
NCT05193370 — Angiotensin II vs. Vasopressin in Septic Shock · Phase 4 · withdrawn

Other recruiting trials for Cardiac Surgery

Currently open trials in the same condition.

NCT06968936 — Long-term Outcomes Sub-Study of Preoperative Combined Iron Therapy · NA · recruiting
NCT07417462 — Transversus Thoracic Muscle Plane Block Versus Pectointercostal Fascial Block for Enhanced Recovery After Cardiac Surger · NA · recruiting
NCT07193719 — Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children · Phase 1, PHASE2 · recruiting
NCT07116343 — Intrapleural Ropivacaine Infusion in Cardiac Surgery · Phase 4 · recruiting
NCT07354841 — Safety and Performance Evaluation of CPB Venous and Arterial Cannulas · NA · recruiting

Other Universität Münster trials

Trials by the same sponsor.

NCT07197307 — Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) · Phase 2 · not yet recruiting
NCT06912529 — Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma · Phase 2 · terminated
NCT06665724 — Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodyna · Phase 1 · completed
NCT06727851 — ESGE-Quality Improvement in Endoscopy: ERCP · enrolling by invitation
NCT06021288 — Standard Dose Continuous Renal Replacement Therapy (CRRT) Versus Low-Dose CRRT ( KETZEREI ) · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05199493 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universität Münster
Last refreshed: 24 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05199493.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing